The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Effect of Ziv-Aflibercept in the Bevacizumab Pre-Treated Subgroup of Patients in VELOUR

Paulo Marcelo Hoff, MD, PhD, FACP
Published Online: 7:19 PM, Sun June 1, 2014
Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses a trial presented at the 2014 ASCO Annual Meeting that looked at the consistency of effect of ziv-aflibercept in the bevacizumab pre-treated subgroup of patients in the VELOUR trial stratified by first-line progression ≥ 9 months versus < 9 months.

<<< Back to the ASCO 2014 conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.